Compassionate Care Alliance
Patient-led nonprofit advocating for expanded access to psychedelic medicine for seriously ill patients who have exhausted conventional treatment options — including right-to-try frameworks for psilocybin.
Type: advocacy
Location: National
Membership: Open to patients, families, advocates
Venues: Virtual and national chapter meetings
Activities: Expanded access advocacy, right-to-try psychedelics, patient testimonials, policy work
About
The Compassionate Care Alliance focuses specifically on the population that existing access frameworks — clinical trials, Oregon service centers — do not adequately serve: seriously ill patients who need treatment now, not after FDA approval.
The alliance advocates for expanded access programs (also called compassionate use) that allow psilocybin use outside clinical trial settings for patients with terminal illness or treatment-resistant conditions. It also supports right-to-try legislation at the state and federal level.
Patient testimonials and lived experience are central to the organization's advocacy approach — amplifying stories of people who found benefit through psilocybin after conventional treatment failed, and who want others to have access without having to travel internationally or participate in controlled trials.
The alliance works closely with MAPS, the Drug Policy Alliance, and state-level advocacy organizations to advance policy change.
Why It Matters
The most urgently ill patients cannot wait for FDA approval — which is years away at minimum. Compassionate access frameworks are the bridge that allows people with terminal illness and treatment-resistant conditions to access psilocybin therapy now.
